Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Stem Cells. 2013 May;31(5):906-17. doi: 10.1002/stem.1324.
To investigate the functional involvements of heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) in smooth muscle cell (SMC) differentiation from stem cells, embryonic stem cells were cultivated on collagen IV-coated plates to allow for SMC differentiation. We found that hnRNPA1 gene and protein expression was upregulated significantly during differentiation and coexpressed with SMC differentiation markers in the stem cell-derived SMCs as well as embryonic SMCs of 12.5 days of mouse embryos. hnRNPA1 knockdown resulted in downregulation of smooth muscle markers and transcription factors, while enforced expression of hnRNPA1 enhanced the expression of these genes. Importantly, knockdown of hnRNPA1 also resulted in impairment of SMC differentiation in vivo. Moreover, we demonstrated that hnRNPA1 could transcriptionally regulate SMC gene expression through direct binding to promoters of Acta2 and Tagln genes using luciferase and chromatin immunoprecipitation assays. We further demonstrated that the binding sites for serum response factor (SRF), a well-investigated SMC transcription factor, within the promoter region of the Acta2 and Tagln genes were responsible for hnRNPA1-mediated Acta2 and Tagln gene expression using in vitro site-specific mutagenesis and luciferase activity analyses. Finally, we also demonstrated that hnRNPA1 upregulated the expression of SRF, myocyte-specific enhancer factor 2c (MEF2c), and myocardin through transcriptional activation and direct binding to promoters of the SRF, MEF2c, and Myocd genes. Our findings demonstrated that hnRNPA1 plays a functional role in SMC differentiation from stem cells in vitro and in vivo. This indicates that hnRNPA1 is a potential modulating target for deriving SMCs from stem cells and cardiovascular regenerative medicine.
为了研究异质核核糖核蛋白 A1(hnRNPA1)在干细胞向平滑肌细胞(SMC)分化中的功能作用,我们将胚胎干细胞培养在胶原蛋白 IV 包被的平板上,以允许 SMC 分化。我们发现,hnRNPA1 基因和蛋白表达在分化过程中显著上调,并与干细胞来源的 SMC 以及 12.5 天大的小鼠胚胎中的胚胎 SMC 中的 SMC 分化标志物共表达。hnRNPA1 敲低导致平滑肌标志物和转录因子下调,而 hnRNPA1 的强制表达增强了这些基因的表达。重要的是,hnRNPA1 敲低也导致体内 SMC 分化受损。此外,我们通过荧光素酶和染色质免疫沉淀测定证实,hnRNPA1 可以通过直接结合 Acta2 和 Tagln 基因启动子转录调控 SMC 基因表达。我们进一步证明,血清反应因子(SRF)的结合位点,一个经过充分研究的 SMC 转录因子,在 Acta2 和 Tagln 基因启动子区域内负责 hnRNPA1 介导的 Acta2 和 Tagln 基因表达,使用体外定点诱变和荧光素酶活性分析。最后,我们还证明 hnRNPA1 通过转录激活和直接结合 SRF、肌细胞特异性增强子因子 2c(MEF2c)和心肌调节蛋白基因的启动子,上调 SRF、MEF2c 和 Myocd 的表达。我们的研究结果表明,hnRNPA1 在体外和体内干细胞向 SMC 分化中发挥功能作用。这表明 hnRNPA1 是一种潜在的调节靶点,可用于从干细胞中获得 SMC,并应用于心血管再生医学。